Bruker (BRKR) 10-Q 5 Nov 21 2021 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2021	Nov. 02, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-30833
Entity Registrant Name	BRUKER CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	04-3110160
Entity Address, Address Line One	40 Manning Road
Entity Address, City or Town	Billerica
Entity Address, Postal Zip Code	01821
Entity Address, State or Province	MA
City Area Code	978
Local Phone Number	663-3660
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Trading Symbol	BRKR
Security Exchange Name	NASDAQ
Title of 12(b) Security	Common Stock
Entity Common Stock, Shares Outstanding		151,655,227
Entity Central Index Key	0001109354
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

UNAUDITED CONDENSED CONSOLIDATE

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 573	$ 681.8
Short-term investments	96.8	50
Accounts receivable, net	372.1	335.3
Inventories	732.8	692.3
Assets held for sale	4.5	0
Other current assets	210.1	165.6
Total current assets	1,989.3	1,925
Property, plant and equipment, net	389.4	395.5
Goodwill	324.2	320.4
Intangible assets, net	217.7	229.1
Assets held for sale	0.4	0
Other long-term assets	206.7	179
Total assets	3,127.7	3,049
Current liabilities:
Current portion of long-term debt	109.5	2.2
Accounts payable	141.1	134.6
Customer advances	178.3	189.2
Other current liabilities	492.3	465.9
Total current liabilities	921.2	791.9
Long-term debt	717.5	842.3
Other long-term liabilities	399.1	440.5
Commitments and contingencies (Note 14)
Redeemable noncontrolling interest	0.3	0
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0	0
Common stock, $0.01 par value 260,000,000 shares authorized, 174,835,498 and 174,045,610 shares issued and 151,690,664 and 151,987,081 shares outstanding at September 30, 2021 and December 31, 2020, respectively	1.7	1.7
Treasury stock, at cost, 23,144,834 and 22,058,529 shares at September 30, 2021 and December 31, 2020, respectively	(738.1)	(667)
Accumulated other comprehensive income (loss)	(10.7)	3.7
Other shareholders' equity	1,822.7	1,622.8
Total shareholders' equity attributable to Bruker Corporation	1,075.6	961.2
Noncontrolling interest in consolidated subsidiaries	14	13.1
Total shareholders' equity	1,089.6	974.3
Total liabilities, redeemable noncontrolling interest and shareholders' equity	$ 3,127.7	$ 3,049

UNAUDITED CONDENSED CONSOLIDA_2

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	260,000,000	260,000,000
Common stock, shares issued	174,835,498	174,045,610
Common stock, shares outstanding	151,690,664	151,987,081
Treasury stock, shares	23,144,834	22,058,529

UNAUDITED CONDENSED CONSOLIDA_3

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue	$ 608.9	$ 511.4	$ 1,734.4	$ 1,360
Total cost of revenue	300.2	263.1	866.4	733.2
Gross profit	308.7	248.3	868	626.8
Operating expenses:
Selling, general and administrative	141.3	114.6	407.9	338.2
Research and development	52.1	48.3	162.7	140.9
Other charges, net	2.1	4.2	9.5	12.2
Total operating expenses	195.5	167.1	580.1	491.3
Operating income	113.2	81.2	287.9	135.5
Interest and other income (expense), net	(4.4)	(5.9)	(13.8)	(15.4)
Income before income taxes and noncontrolling interest in consolidated subsidiaries	108.8	75.3	274.1	120.1
Income tax provision	20.7	20	69.5	30
Consolidated net income	88.1	55.3	204.6	90.1
Net income attributable to noncontrolling interests in consolidated subsidiaries	1	1	3.2	1.2
Net income attributable to Bruker Corporation	$ 87.1	$ 54.3	$ 201.4	$ 88.9
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.58	$ 0.35	$ 1.33	$ 0.58
Diluted (in dollars per share)	$ 0.57	$ 0.35	$ 1.32	$ 0.57
Weighted average common shares outstanding:
Basic (in shares)	151.4	153.2	151.5	153.7
Diluted (in shares)	152.8	154.3	153	154.8
Comprehensive income	$ 73.1	$ 64	$ 188.1	$ 110.1
Less: Comprehensive income attributable to noncontrolling interests	0.7	1.4	0.9	1.5
Less: Comprehensive loss attributable to redeemable noncontrolling interest	0	0	0	(0.5)
Comprehensive income attributable to Bruker Corporation	72.4	62.6	187.2	109.1
Product
Total revenue	508.3	419.6	1,441.2	1,111.6
Total cost of revenue	243.5	210.3	700.4	584.1
Service
Total revenue	99	90	287.8	244.3
Total cost of revenue	56.5	52.6	165.3	148.4
Other
Total revenue	1.6	1.8	5.4	4.1
Total cost of revenue	$ 0.2	$ 0.2	$ 0.7	$ 0.7

UNAUDITED CONDENSED CONSOLIDA_4

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Total Shareholders' Equity Attributable to Bruker Corporation	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests in Consolidated Subsidiaries	Redeemable Noncontrolling Interest
Balance at beginning of period at Dec. 31, 2019	$ 917.1	$ 906.8	$ 1.7	$ (543.8)	$ 199.7	$ 1,274.7	$ (25.5)	$ 10.3	$ 21.1
Balance (in shares) at Dec. 31, 2019			154,155,798	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7	0.7			0.7
Stock options exercised (in shares)			30,182
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			40,516
Stock based compensation	3	3			3
Dividends declared to common stockholders	(7.4)	(6.2)				(6.2)		(1.2)
Acquired remaining 20% interest in Hain LifeScience GmbH	(1.3)	(1.3)				(1.3)			(20.6)
Consolidated net income	10.6	10.5				10.5		0.1
Other comprehensive income (loss)	2	2.2					2.2	(0.2)	(0.5)
Balance at end of period at Mar. 31, 2020	924.6	915.6	$ 1.7	$ (543.8)	203.3	1,277.7	(23.3)	9
Balance (in shares) at Mar. 31, 2020			154,226,496	19,346,577
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.3	1.3			1.3
Stock options exercised (in shares)			61,968
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			3,510
Stock based compensation	2.8	2.8			2.8
Shares purchased	(50)	(50)		$ (50)
Shares purchased (in shares)			(1,214,282)	1,214,282
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	24.2	24.1				24.1		0.1
Other comprehensive income (loss)	9.9	9.8					9.8	0.1
Balance at end of period at Jun. 30, 2020	906.6	897.4	$ 1.7	$ (593.8)	207.3	1,295.7	(13.5)	9.2
Balance (in shares) at Jun. 30, 2020			153,077,692	20,560,859
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.5	0.5			0.5
Stock options exercised (in shares)			25,461
RSU vested	(1.2)	(1.2)			(1.2)
RSU vested (in shares)			208,652
Stock based compensation	4.1	4.1			4.1
Shares purchased	(5)	(5)		$ (5)
Shares purchased (in shares)			(127,278)	127,278
Dividends declared to common stockholders	(6.3)	(6.3)				(6.3)
Consolidated net income	55.3	54.3				54.3		1
Other comprehensive income (loss)	8.7	8.3					8.3	0.4
Balance at end of period at Sep. 30, 2020	962.7	952.1	$ 1.7	$ (598.8)	210.7	1,343.7	(5.2)	10.6
Balance (in shares) at Sep. 30, 2020			153,184,527	20,688,137
Balance at beginning of period at Dec. 31, 2020	974.3	961.2	$ 1.7	$ (667)	216.3	1,406.5	3.7	13.1	0
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1.2	1.2			1.2
Stock options exercised (in shares)			65,312
RSU vested	(0.1)	(0.1)			(0.1)
RSU vested (in shares)			21,821
Stock based compensation	3.4	3.4			3.4
Shares purchased	(32.8)	(32.8)		$ (32.8)
Shares purchased (in shares)			(530,729)	530,729
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	57.8	56.7				56.7		1.1
Other comprehensive income (loss)	(16)	(15.8)					(15.8)	(0.2)
Balance at end of period at Mar. 31, 2021	981.7	967.7	$ 1.7	$ (699.8)	220.8	1,457.1	(12.1)	14
Balance (in shares) at Mar. 31, 2021			151,543,485	22,589,258
Balance at beginning of period at Dec. 31, 2020	$ 974.3	961.2	$ 1.7	$ (667)	216.3	1,406.5	3.7	13.1	0
Balance (in shares) at Dec. 31, 2020			151,987,081	22,058,529
Increase (Decrease) in Stockholders' Equity
Stock options exercised (in shares)	515,692
Balance at end of period at Sep. 30, 2021	$ 1,089.6	1,075.6	$ 1.7	$ (738.1)	233	1,589.7	(10.7)	14	0.3
Balance (in shares) at Sep. 30, 2021			151,690,664	23,144,834
Balance at beginning of period at Mar. 31, 2021	981.7	967.7	$ 1.7	$ (699.8)	220.8	1,457.1	(12.1)	14
Balance (in shares) at Mar. 31, 2021			151,543,485	22,589,258
Increase (Decrease) in Stockholders' Equity
Stock options exercised	1	1			1
Stock options exercised (in shares)			64,783
RSU vested	0	0			0
RSU vested (in shares)			1,780
Stock based compensation	3.6	3.6			3.6
Shares purchased	(38.3)	(38.3)		$ (38.3)
Shares purchased (in shares)			(555,576)	555,576
Dividends declared to common stockholders	(6)	(6)				(6)
Formation of Acuity Spatial Genomics Inc.									0.3
Consolidated net income	58.7	57.6				57.6		1.1
Other comprehensive income (loss)	14.7	16.4					16.4	(1.7)
Balance at end of period at Jun. 30, 2021	1,015.4	1,002	$ 1.7	$ (738.1)	225.4	1,508.7	4.3	13.4	0.3
Balance (in shares) at Jun. 30, 2021			151,054,472	23,144,834
Increase (Decrease) in Stockholders' Equity
Stock options exercised	8.3	8.3			8.3
Stock options exercised (in shares)			385,597
RSU vested	(4.5)	(4.5)			(4.5)
RSU vested (in shares)			250,595
Stock based compensation	3.8	3.8			3.8
Dividends declared to common stockholders	(6.1)	(6.1)				(6.1)
Consolidated net income	88.1	87.1				87.1		1
Other comprehensive income (loss)	(15.4)	(15)					(15)	(0.4)
Balance at end of period at Sep. 30, 2021	$ 1,089.6	$ 1,075.6	$ 1.7	$ (738.1)	$ 233	$ 1,589.7	$ (10.7)	$ 14	$ 0.3
Balance (in shares) at Sep. 30, 2021			151,690,664	23,144,834

UNAUDITED CONDENSED CONSOLIDA_5

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTEREST AND SHAREHOLDERS' EQUITY (Parenthetical) - $ / shares	3 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020
Dividends declared (per share)	$ 0.04	$ 0.04	$ 0.04	$ 0.04	$ 0.04	$ 0.04
Hain
Interest acquired	20.00%

UNAUDITED CONDENSED CONSOLIDA_6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities:
Consolidated net income	$ 204.6	$ 90.1
Adjustments to reconcile consolidated net income to cash flows from operating activities:
Depreciation and amortization	66.1	58.7
Stock-based compensation expense	11.9	10.9
Deferred income taxes	(6.5)	0.5
Other non-cash expenses, net	24.8	25.5
Changes in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable	(47.7)	36.9
Inventories	(81.3)	(109.7)
Accounts payable and accrued expenses	45.9	(15.3)
Income taxes payable, net	(33.4)	(9.1)
Deferred revenue	19.4	20.1
Customer advances	(9.5)	32.4
Other changes in operating assets and liabilities, net	(50.5)	(11.8)
Net cash provided by operating activities	143.8	129.2
Cash flows from investing activities:
Purchases of short-term investments	(48)	(100)
Maturities of short-term investments	0.7	56.1
Purchases of investments held to maturity	(0.5)	0
Cash paid for acquisitions, net of cash acquired	(45)	(58.8)
Purchases of property, plant and equipment	(63.6)	(68.4)
Proceeds from sales of property, plant and equipment	4	0.1
Net proceeds from cross-currency swap agreements	8.6	7.1
Net cash used in investing activities	(143.8)	(163.9)
Cash flows from financing activities:
Repayments of revolving lines of credit	0	(305.1)
Proceeds from revolving lines of credit		297.5
Repayment of other debt	(2.2)	(0.4)
Proceeds from other debt	0.4	0
Payment of deferred financing costs		(0.1)
Proceeds from issuance of common stock, net	5.9	1.1
Payment of contingent consideration	(0.4)	(6.2)
Payment of dividends to common stockholders	(18.2)	(18.5)
Purchases of common stock	(71.1)	(54.4)
Cash payments to noncontrolling interest	0	(1.2)
Net cash used in financing activities	(85.6)	(87.3)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(23.4)	10.7
Net change in cash, cash equivalents and restricted cash	(109)	(111.3)
Cash, cash equivalents and restricted cash at beginning of period	685.5	681.9
Cash, cash equivalents and restricted cash at end of period	576.5	570.6
Supplemental disclosure of cash flow information:
Restricted cash period beginning balance	3.7	3.6
Restricted cash period ending balance	$ 3.5	$ 3.5

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2021
Description of Business
Description of Business	1. Description of Business Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving n e The Company has four operating segments, Bruker BioSpin Group, Bruker CALID Group, Bruker Scientific Instruments (BSI) Nano Group Bruker Energy & Supercon Technologies (BEST) BSI Life Science segment, BSI NANO segment and BEST. For financial reporting purposes, the Bruker BioSpin Bruker BioSpin Bruker CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection) for-profit The BSI NANO segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services, and products and services for spatial genomics research. Customers of the BSI NANO segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis. The BEST reportable segment develops and manufactures superconducting and non-superconducting The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2021 and December 31, 2020, and for the three and nine months ended September 30, 2021 and 2020, have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Accordingly, the financial information presented herein does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year. At September 30, 2021, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K Risks & Uncertainties The Company is subject to risks common to its industry including, but not limited to, global economic conditions, rapid technological change, government and academic funding levels, the impact of the COVID-19 The impact of the COVID-19 Impacts to the Company’s business included temporary closures in 2020 of many of the Company’s government and university customers and suppliers, disruptions or restrictions on employees’ and customers’ ability to travel, and delays in product installations or shipments to and from affected countries. In an effort to halt the outbreak of COVID-19, COVID-19 re-opening re-openings pre-pandemic COVID-19 re-opened pre-pandemic Further, on September 9, 2021, President Biden directed the Department of Labor’s Occupational Safety and Health Administration (“OSHA”) to issue an Emergency Temporary Standard (“ETS”) requiring that all employers with at least 100 employees ensure that their employees are fully vaccinated for COVID-19 COVID-19 COVID-19 COVID-19 The Company has experienced supply chain interruptions as a result of the COVID-19 pandemic. Various factors, including increased demand for certain components and production delays and other natural events and disasters, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, can result in significant additional costs and inefficiencies in manufacturing. A shortage of key components may cause a significant disruption to the Company’s production activities, which could have a substantial adverse effect on the Company’s financial condition or results of operations. If the Company is unsuccessful in resolving any such component shortages in a timely manner, the Company could experience a significant adverse impact on the timing of its revenue, a possible loss of revenue, or an increase in manufacturing costs, any of which would have a material adverse impact on the Company’s operating results. The Company is continuing to monitor and assess the effects of the COVID-19 The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases estimates on historical experience and on various other assumptions that they believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the COVID-19 COVID-19, COVID-19 COVID-19

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Recent Accounting Pronouncements
Recent Accounting Pronouncements	2. Recent Accounting Pronouncements In March 2020, the FASB issued Accounting Standards Updates (“ASU”) No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting 2020-04”), held-to-maturity. 2021-01, In December 2019, the FASB issued ASU 2019-12 - Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue
Revenue	3. Revenue The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue by Group: Bruker BioSpin $ 186.5 $ 152.1 $ 494.4 $ 398.1 Bruker CALID 194.2 171.3 579.9 444.5 Bruker Nano 174.9 147.1 504.6 392.7 BEST 57.0 43.8 166.0 134.8 Eliminations (3.7 ) (2.9 ) (10.5 ) (10.1 ) Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue by End Customer Geography: United States $ 163.2 $ 120.1 $ 442.0 $ 332.1 Germany 55.5 50.4 186.4 134.9 Rest of Europe 155.4 142.9 459.9 357.7 Asia Pacific 191.6 160.0 525.8 433.3 Other 43.2 38.0 120.3 102.0 Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue recognized at a point in time $ 530.8 $ 442.2 $ 1,503.0 $ 1,174.0 Revenue recognized over time 78.1 69.2 231.4 186.0 Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Remaining Performance Obligations Remaining performance obligations represent the aggregate transaction price allocated to a promise to transfer a good or service that is fully or partially unsatisfied at the end of the period. As of September 30, 2021, remaining performance obligations were approximately $2,035.9 one Contract Balances The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets) and deferred revenue, customer deposits and billings in excess of revenue recognized (contract liabilities) on the Company’s unaudited condensed consolidated balance sheets. Contract assets— Contract liabilities— COVID-19.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Asset Acquisition [Abstract]
Acquisitions	4. Acquisitions The impact of all acquisitions and investments in other entities during the nine months ended September 30, 2021, individually and collectively, on revenues, net income and total assets was not material and accordingly, pro forma financial information reflecting all acquisitions has not been presented. 2021 SCI Instruments On August 24, 2021, the Company acquired SCI Instruments (“SCI”), a privately held company, for a purchase price of $28.0 million with the potential for additional consideration of up to $4.0 million based on revenue and gross margin achievements in the calendar years 2022 and 2023. SCI is a manufacturer of advanced metrology systems and analysis software and serves major companies in the semiconductor, optoelectronics, data storage, display, MEMS, and optical coating industries. SCI will be integrated into the BSI Nano segment Consideration Transferred: Cash paid $ 28.0 Fair value of contingent consideration 1.0 Working capital adjustment (1.0 ) Total consideration transferred $ 28.0 Allocation of Consideration Transferred: Inventories $ 1.0 Other current and non-current 1.0 Intangible assets: Technology 7.1 Customer relationships 6.4 Trade name 0.4 Backlog 1.2 Goodwill 12.6 Liabilities assumed (1.7 ) Total consideration allocated $ 28.0 The preliminary fair value allocation included contingent consideration in the amount of $1.0 million, which represented the estimated fair value of future payments to the former shareholders of SCI based on achieving revenue and gross margin targets for the calendar years 2022 and 2023. The Company expects to complete the fair value allocation during the measurement period. The amortization period for the intangible assets acquired is ten years for the trade name and technology, and nine years for the customer relationships. The backlog intangible asset is expected to be fully amortized by December 31, 2021. In addition to the SCI acquisition, in 2021 the Company completed acquisitions that complemented the Company’s existing product offerings. The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions): Name of Acquisition Date Acquired Segment Total Cash Creative Instruments July 1, 2021 BSI Life Science $ 1.0 $ 1.0 SVXR, Inc. September 9, 2021 BSI Nano 14.0 11.9 $ 15.0 $ 12.9 In addition to the acquisitions noted above, in the nine months ended September 30, 2021, the Company made investments in businesses complementary to its own portfolio. The following table reflects the consideration transferred and the respective reporting segment for these investments (in millions): Name Acquisition / Date Acquired Segment Consideration Cash Glycopath Inc. Investment February 18, 2021 BSI Life Science $ 2.0 $ 2.0 IonPath Inc. Investment March 18, 2021 BSI Life Science 2.0 2.0 Olaris, Inc. Investment September 23, 2021 BSI Life Science 0.5 0.5 $ 4.5 $ 4.5

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventories
Inventories	5. Inventories Inventories consisted of the following (dollars in millions): September 30, December 31, Raw materials $ 209.9 $ 198.8 Work-in-process 272.5 245.7 Finished goods 155.9 152.1 Demonstration units 94.5 95.7 Inventories $ 732.8 $ 692.3 Finished goods include in-transit inventory-in-transit

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets
Goodwill and Intangible Assets	6. Goodwill and Intangible Goodwill The following table sets forth the changes in the carrying amount of goodwill (dollars in millions): Total Balance at December 31, 2020 $ 320.4 Current period additions/adjustments 12.7 Foreign currency impact (8.9 ) Balance at September 30, 2021 $ 324.2 Intangible Assets The following is a summary of intangible assets, excluding goodwill (dollars in millions): September 30, 2021 December 31, 2020 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Existing technology and related patents $ 308.4 $ (202.1 ) $ 106.3 $ 309.8 $ (194.6 ) $ 115.2 Customer relationships 155.1 (54.6 ) 100.5 148.3 (45.4 ) 102.9 Trade names 15.1 (5.4 ) 9.7 15.2 (4.4 ) 10.8 Other 1.8 (0.6 ) 1.2 0.3 (0.1 ) 0.2 Intangible assets $ 480.4 $ (262.7 ) $ 217.7 $ 473.6 $ (244.5 ) $ 229.1 For the three months ended September 30, 2021 and 2020, the Company recorded amortization expense of $9.3 million and $9.0 million, respectively, related to intangible assets subject to amortization. For the nine months ended September 30, 2021 and 2020, the Company recorded amortization expense of $27.3 million and $26.7 million, respectively, related to intangible assets subject to amortization.

Debt

Debt	9 Months Ended
	Sep. 30, 2021
Debt
Debt	7. Debt The Company’s debt obligations consisted of the following (dollars in millions): September 30, December 31, US Dollar notes under the 2012 Note Purchase Agreement $ 205.0 $ 205.0 CHF notes (in dollars) under the 2019 Note Purchase Agreement 318.1 335.5 US Dollar notes under the 2019 Term Loan 300.0 300.0 Unamortized debt issuance costs (2.1 ) (2.4 ) Finance lease obligations and other loans 6.0 6.4 Total debt 827.0 844.5 Current portion of long-term debt (109.5 ) (2.2 ) Total long-term debt, less current portion $ 717.5 $ 842.3 The following is a summary of the maximum commitments and the net amounts available to the Company under its credit agreements and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2021 (in millions): Weighted Total Amount Outstanding Outstanding Total 2019 Credit Agreement 1.3 % $ 600.0 $ — $ 0.1 $ 599.9 Bank guarantees and working capital line varies 115.2 — 115.2 — Total revolving lines of credit $ 715.2 $ — $ 115.3 $ 599.9 As of September 30, 2021, the Company was in compliance with the financial covenants of all debt agreements. As of September 30, 2021, the Company had several cross-currency and interest rate swap agreements with a notional value of $150.0 million of U.S. to Swiss Franc and a notional value of $355.0 million of U.S. to Euro to hedge the variability in the movement of foreign currency exchange rates on portions of our Euro and Swiss Franc denominated net asset investments. These agreements qualify for hedge accounting and accordingly the changes in fair value of the derivative are recorded in other comprehensive income as part of foreign currency translation adjustments and remain in accumulated comprehensive income (loss) attributable to Bruker Corporation in shareholders’ equity until the sale or substantial liquidation of the foreign operation. The difference between the interest rate received and paid under the interest rate and cross-currency swap agreements is recorded in interest and other income (expenses) in the consolidated statements of income and comprehensive income. As a result of entering into these agreements, the Company lowered net interest expense by $1.4 million during each of

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Sep. 30, 2021
Fair Value of Financial Instruments
Fair Value of Financial Instruments	8. Fair Value of Financial The following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in millions): September 30, 2021 Total Quoted Prices Significant Significant Assets: Time deposits and money market funds $ 12.4 $ — $ 12.4 $ — Short-term investments 96.8 — 96.8 — Interest rate and cross currency swap agreements 7.1 — 7.1 — Fixed price commodity contracts 0.8 — 0.8 — Debt securities available for sale 1.2 — — 1.2 Total assets recorded at fair value $ 118.3 $ — $ 117.1 $ 1.2 Liabilities: Contingent consideration $ 5.6 $ — $ — $ 5.6 Hybrid instrument liability 14.3 — — 14.3 Interest rate and cross currency swap agreements 29.0 — 29.0 — Embedded derivatives in purchase and delivery contracts 0.1 — 0.1 — Forward currency contracts 0.7 — 0.7 — Long-term fixed interest rate debt 535.1 — 535.1 — Total liabilities recorded at fair value $ 584.8 $ — $ 564.9 $ 19.9 December 31, 2020 Total Quoted Prices Significant Significant Assets: Time deposits and money market funds $ 183.2 $ — $ 183.2 $ — Short-term investments 50.0 — 50.0 — Interest rate and cross currency swap agreements 7.6 — 7.6 — Forward currency contracts 2.1 — 2.1 — Embedded derivatives in purchase and delivery contracts 0.1 — 0.1 — Fixed price commodity contracts 3.1 — 3.1 — Debt securities available for sale 1.2 — — 1.2 Total assets recorded at fair value $ 247.3 $ — $ 246.1 $ 1.2 Liabilities: Contingent consideration $ 4.3 $ — $ — $ 4.3 Hybrid instrument liability 13.9 — — 13.9 Interest rate and cross currency swap agreements 61.5 — 61.5 — Forward currency contracts 0.4 — 0.4 — Long-term fixed interest rate debt 549.8 — 549.8 — Total liabilities recorded at fair value $ 629.9 $ — $ 611.7 $ 18.2 The Company’s financial instruments consist primarily of cash equivalents, short-term investments, restricted cash, derivative instruments consisting of forward foreign exchange contracts, cross-currency interest rate swap agreements, commodity contracts, derivatives embedded in certain purchase and sale contracts, derivatives embedded within noncontrolling interests, accounts receivable, accounts payable, contingent consideration and long-term debt. The carrying amounts of the Company’s cash equivalents, short-term investments and restricted cash, accounts receivable, borrowings under a revolving credit agreement and accounts payable approximate fair value because of their short-term nature. Derivative assets and liabilities are measured at fair value on a recurring basis. The Company’s long-term debt consists principally of a note purchase agreement entered into in 2012 and a revolving credit agreement, long term loan agreement and note purchase agreement entered into in 2019. The Company has evaluated the estimated fair value of financial instruments using available market information and management’s estimates. The use of different market assumptions and/or estimation methodologies could have a significant effect on the estimated fair value amounts. The Company measures certain assets and liabilities at fair value with changes in fair value recognized in earnings. Fair value treatment may be elected either upon initial recognition of an eligible asset or liability or, for an existing asset or liability, if an event triggers a new basis of accounting. The Company did not elect to remeasure any of its existing financial assets or liabilities and did not elect the fair value option for any financial assets or liabilities which originated during the nine months ended September 30, 2021 or 2020. The fair value of the long-term fixed interest rate debt, which has been classified as Level 2 was based on market and observable sources with similar maturity dates. The carrying value of our variable rate debt approximates its fair value at September 30, 2021 and December 31, 2020. On a quarterly basis, the Company reviews its short-term investments to determine if there have been any events that could create an impairment. None were noted for the nine months ended September 30, 2021 or 2020. Contingent consideration recorded within other current liabilities represents the estimated fair value of future payments to the former shareholders as part of certain acquisitions. The contingent consideration is primarily based on the applicable acquired company achieving annual revenue and gross margin targets in certain years as specified in the relevant purchase and sale agreement. The Company initially values the contingent consideration on the acquisition date by using a Monte Carlo simulation or an income approach method. The Monte Carlo method models future revenue and costs of goods sold projections and discounts the average results to present value. The income approach method involves calculating the earnout payment based on the forecasted cash flows, adjusting the future earnout payment for the risk of reaching the projected financials, and then discounting the future payments to present value by the counterparty risk. The counterparty risk considers the risk of the buyer having the cash to make the earnout payments and is commensurate with a cost of debt over an appropriate term. The following table sets forth the changes in contingent consideration liabilities (dollars in millions): Balance at December 31, 2020 $ 4.3 Current period additions 1.9 Current period adjustments (0.1 ) Current period settlements (0.4 ) Foreign currency effect (0.1 ) Balance at September 30, 2021 $ 5.6 As part of the Mestrelab Research, S.L. (“Mestrelab”) acquisition, the Company entered into an agreement with the noncontrolling interest holders that provides the Company with the right to purchase, and the noncontrolling interest holders with the right to sell, the remaining 49% of Mestrelab for cash at a contractually defined redemption value. These rights (an embedded derivative) are exercisable beginning in 2022 and can be accelerated, at a discounted redemption value, upon certain events related to post combination services. As the option is tied to continued employment, the Company classified the hybrid instrument (noncontrolling interest with an embedded derivative) as a long-term liability on the consolidated balance sheet. Subsequent to the acquisition, the carrying value of the hybrid instrument is remeasured to fair value with changes recorded to stock-based compensation expense in proportion to the requisite service period vested. The hybrid instrument is classified as Level 3 in the fair value hierarchy. The following table sets forth the changes in hybrid instrument liability (dollars in millions): Balance at December 31, 2020 $ 13.9 Current period adjustments 1.1 Foreign currency effect (0.7 ) Balance at September 30, 2021 $ 14.3

Derivative Instruments and Hedg

Derivative Instruments and Hedging Activities	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities
Derivative Instruments and Hedging Activities	9. Derivative Instruments and Hedging Activities Commodity Price Risk Management At September 30, 2021 and December 31, 2020, the Company had fixed price commodity contracts with notional amounts aggregating $4.5 million and $8.8 million, respectively. As commodity contracts settle, gains (losses) as a Foreign Exchange Rate Risk The Company had notional amounts outstanding under forward currency contracts and cross-currency interest rate swap agreements as of (dollars in millions): September 30, 2021 December 31, 2020 Notional Fair Value Notional Fair Value Forward currency contracts (1): Assets $ 10.4 $ — $ 175.8 $ 2.1 Liabilities 114.1 (0.7 ) 102.5 (0.4 ) Cross-currency and interest rate swap agreements (2): Liabilities 505.0 (21.9 ) 505.0 (53.9 ) Long-term debt Liabilities 318.1 (20.2 ) 335.5 (37.6 ) Total $ 947.6 $ (42.8 ) $ 1,118.8 $ (89.8 ) (1) Derivatives not designated as accounting hedges. (2) Derivatives designated as accounting hedges. In addition, the Company periodically enters into purchase and sales contracts denominated in currencies other than the functional currency of the parties to the transaction. The Company accounts for these transactions separately valuing the “embedded derivative” component of these contracts. The contracts, denominated in currencies other than the functional currency of the transacting parties, amounted to $6.0 million for the delivery of products and $7.0 million for the purchase of products at September 30, 2021 and $7.5 million for the delivery of products and $4.8 million for the purchase of products at December 31, 2020. The changes in the fair value of these embedded derivatives are recorded in interest and other income (expense), net in the consolidated statements of income and comprehensive income. The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets for the periods ended as follows (dollars in millions): September 30, 2021 December 31, 2020 Derivatives designated as hedging instruments Interest rate cross-currency swap agreements Other current assets $ 7.1 $ 7.6 Other current liabilities (8.5 ) (4.3 ) Other long-term liabilities (20.5 ) (57.2 ) (21.9 ) (53.9 ) Long-term debt Long-term debt (20.2 ) (37.6 ) Total derivatives designated as hedging instruments $ (42.1 ) $ (91.5 ) Derivatives not designated as hedging instruments Forward currency contracts Other current assets $ — $ 2.1 Other current liabilities (0.7 ) (0.4 ) Embedded derivatives in purchase and delivery contracts Other current assets — 0.1 Other current liabilities (0.1 ) — Fixed price commodity contracts Other current assets 0.8 3.1 Total derivatives not designated as hedging instruments — 4.9 Total derivatives $ (42.1 ) $ (86.6 ) The following is a summary of the activity included in the unaudited condensed consolidated statements of income and comprehensive income related to the derivative instruments described above (in millions): Location of gain (loss) recognized in income on derivative Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Derivatives not designated as hedging instruments Forward currency contracts Interest and other income (expense), net $ (0.9 ) $ (0.2 ) $ (4.8 ) $ (0.4 ) Embedded Interest and other income (expense), net 0.1 (0.1 ) (0.3 ) 0.8 (0.8 ) (0.3 ) (5.1 ) 0.4 Derivatives designated as cash flow hedging instruments Interest rate cross-currency swap agreements Interest and other income (expense), net $ (1.2 ) $ (1.1 ) $ (3.5 ) $ (1.9 ) Derivatives designated as net investment hedging instruments Interest rate cross-currency swap agreements Interest and other income (expense), net 2.6 2.5 7.6 7.7 1.4 1.4 4.1 5.8 Total $ 0.6 $ 1.1 $ (1.0 ) $ 6.2 Amount of unrealized gain (loss) on contracts recognized other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, Financial Statement Classification 2021 2020 2021 2020 Derivatives designated as cash flow hedging instruments Interest rate cross-currency Accumulated other comprehensive income, net of tax $ 0.9 $ (0.2 ) $ 11.5 $ (22.1 ) $ 0.9 $ (0.2 ) $ 11.5 $ (22.1 ) Derivatives designated as net investment hedging instruments Interest rate cross-currency swap agreements Accumulated other comprehensive income, net of tax $ 7.4 $ (21.9 ) $ 25.6 $ (0.3 ) Long-term debt Accumulated other comprehensive income, net of tax 2.2 (8.2 ) 22.2 (15.3 ) $ 9.6 $ (30.1 ) $ 47.8 $ (15.6 ) Total $ 10.5 $ (30.3 ) $ 59.3 $ (37.7 )

Provision for Income Taxes

Provision for Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Taxes
Provision for Income Taxes	10. Provision for Income Taxes The Company accounts for income taxes using the asset and liability approach by recognizing deferred tax assets and liabilities for the expected future tax consequences of differences between the financial statement basis and the tax basis of assets and liabilities, calculated using enacted tax rates in effect for the year in which the differences The income tax provision for the three months ended September 30, 2021 and 2020 was $20.7 million and $20.0 million, respectively, representing effective tax rates of 19.0% and 26.6%, respectively. The decrease in our effective tax rate was primarily due to the jurisdictional profit mix and the impact of favorable discrete items in the period. The increase in the Company’s effective tax rate was primarily due to the increase in profit before income tax and the jurisdictional profit mix, partially offset by the impact of discrete items in the period. As of September 30, 2021 and December 31, 2020, the Company had gross unrecognized tax benefits, excluding penalties and interest, of approximately $34.8 million and $22.7 million, respectively, which, if recognized, would result in a reduction of the Company’s effective tax rate. The Company recognizes penalties and interest related to unrecognized tax benefits in the provision for income taxes. As of September 30, 2021 and December 31, 2020, approximately $2.3 million and $1.8 million, respectively, of accrued interest and penalties related to uncertain tax positions was included in other long-term liabilities on the Company’s unaudited condensed consolidated balance sheets. Penalties and interest of $0.2 million and $0.1 million were recorded in the provision for income taxes for unrecognized tax benefits during both the three months ended September 30, 2021 and 2020. Penalties and interest of $0.6 million and $0.4 million was recorded in the provision for income taxes for unrecognized tax benefits during the nine months ended September 30, 2021 and 2020, respectively. The Company files tax returns in the United States, which includes federal, state and local jurisdictions, and many foreign jurisdictions with varying statutes of limitations. The Company considers Germany, the United States and Switzerland to be its significant tax jurisdictions. The majority of the Company’s earnings are derived in Germany and Switzerland. Accounting for the various federal and local taxing authorities, the statutory rates for 2021 are approximately 30.0% and 20.0% for Germany and Switzerland, respectively. The mix of earnings in those two jurisdictions resulted in an increase of 5.5% from the U.S. statutory rate of 21.0% in the nine months ended September 30, 2021.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share
Earnings Per Share	11. Earnings Per Share The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income attributable to Bruker Corporation, as reported $ 87.1 $ 54.3 $ 201.4 $ 88.9 Weighted average shares outstanding: Weighted average shares outstanding-basic 151.4 153.2 151.5 153.7 Effect of dilutive securities: Stock options and restricted stock awards and units 1.4 1.1 1.5 1.1 152.8 154.3 153.0 154.8 Net income per common share attributable to Bruker Corporation shareholders: Basic $ 0.58 $ 0.35 $ 1.33 $ 0.58 Diluted $ 0.57 $ 0.35 $ 1.32 $ 0.57 The following common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Stock options — 0.3 — 0.1 Unvested restricted stock units — 0.2 — 0.1

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2021
Shareholders' Equity
Shareholders' Equity	12. Shareholders’ Equity Share Repurchase Program In May 2019, the Company’s Board of Directors approved a stock repurchase plan (the “2019 Repurchase Program”) authorizing the purchase of common stock in the amount of up to $300.0 million from time to time, in amounts, at prices, and at such times as management deems appropriate, subject to market conditions, legal requirements and other considerations. During the nine months ended September 30, 2021, the Company repurchased a total of 555,602 shares at an aggregate cost of $34.5 million under the 2019 Repurchase Program. We completed the 2019 Repurchase Program in April 2021, after reaching the maximum cumulative spend. In May 2021, the Company’s Board of Directors approved a stock repurchase plan (the “2021 Repurchase Program”) authorizing the purchase of common stock in the amount of up to $500.0 million from time to time over a two Accumulated Other Comprehensive Income (Loss) The following is a summary of comprehensive income (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Consolidated net income $ 88.1 $ 55.3 $ 204.6 $ 90.1 Foreign currency translation adjustments (26.6 ) 38.9 (80.2 ) 42.8 Derivatives designated as hedging instruments, net of tax 10.5 (30.3 ) 59.3 (37.7 ) Pension liability adjustments, net of tax 1.1 0.1 4.4 14.9 Net comprehensive income 73.1 64.0 188.1 110.1 Less: Comprehensive income attributable to noncontrolling interests 0.7 1.4 0.9 1.5 Less: Comprehensive loss attributable to redeemable noncontrolling interest — — — (0.5 ) Comprehensive income attributable to Bruker Corporation $ 72.4 $ 62.6 $ 187.2 $ 109.1 The following is a summary of the components of Foreign Derivatives Pension Accumulated Balance at December 31, 2020 $ 140.9 $ (91.5 ) $ (45.7 ) $ 3.7 Other comprehensive (loss) income before reclassifications, net of tax (78.1 ) 59.3 2.2 (16.6 ) Realized loss on amounts reclassified from other comprehensive income, net of tax — — 2.2 2.2 Net current period other comprehensive (loss) income (78.1 ) 59.3 4.4 (14.4 ) Balance at September 30, 2021 $ 62.8 $ (32.2 ) $ (41.3 ) $ (10.7 ) Stock-Based Compensation The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Costs of product revenue $ 0.6 $ 0.6 $ 1.6 $ 1.5 Selling, general and administrative 2.6 2.9 7.6 6.9 Research and development 0.6 0.6 1.6 1.5 Total stock-based compensation $ 3.8 $ 4.1 $ 10.8 $ 9.9 In addition to the awards above, the Company recorded stock-based compensation expense within other charges, net of $0.3 million in the three months ended September 30, 2021 and 2020, and $1.1 million and $1.0 million in the nine months ended September 30, 2021 and 2020, respectively, related to the 2018 acquisition of Mestrelab. At September 30, 2021, the Company expects to recognize pre-tax Company pre-tax Company’s 2016 Incentive Compensation Stock options to purchase the Company’s common stock are periodically awarded to executive officers and other employees of the Company subject to a vesting period of three to four years. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. Assumptions regarding volatility, expected life, dividend yield and risk-free interest rates are required for the Black-Scholes model and are presented in the table below: Nine months ended September 30, 2021 2020 Risk-free interest rates 0.62 % 0.23 % Expected life 4.43 years 5.14 years Volatility 34 % 34 % Expected dividend yield 0.20 % 0.37 % Stock option activity was as follows: Shares Subject Weighted Weighted Aggregate Outstanding at December 31, 2020 1,856,176 $ 25.32 Granted 79,632 $ 85.10 Exercised (515,692 ) $ 20.40 Forfeited/Expired — $ — Outstanding at September 30, 2021 1,420,116 $ 30.45 4.3 $ 68.2 Exercisable at September 30, 2021 1,158,452 $ 24.66 3.8 $ 61.9 Exercisable and expected to vest at September 30, 2021 (a) 1,384,099 $ 29.68 4.2 $ 67.5 (a) Represents the number of vested options at September 30, 2021, plus the number of unvested options at September 30, 2021 that are ultimately expected to vest based on our estimated forfeiture rate. (b) The aggregate intrinsic value is based on the positive difference between the exercise price of the underlying options and the quoted price of our common stock on September 30, 2021. The total intrinsic value of options exercised was $31.8 million and $2.2 million for the nine months ended September 30, 2021 and 2020, respectively. Restricted stock unit activity was as follows: Shares Subject Weighted Outstanding at December 31, 2020 805,052 $ 39.63 Granted 216,692 $ 78.01 Vested (329,840 ) $ 37.07 Forfeited (19,043 ) $ 43.52 Outstanding at September 30, 2021 672,861 $ 53.14 The total fair value of restricted stock units vested was $26.6 million and $12.8 million for the nine months ended September 30, 2021 and 2020, respectively.

Other Charges, Net

Other Charges, Net	9 Months Ended
	Sep. 30, 2021
Other Charges (Gain), Net
Other Charges, Net	13. Other Charges, Net The components of other charges, net were as Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Information technology transformation costs $ 1.1 $ 0.5 $ 2.6 $ 1.8 Professional fees incurred in connection with investigation matters 0.1 0.3 0.1 4.8 Restructuring charges 0.9 1.7 3.6 4.4 Acquisition-related charges 0.6 0.9 3.8 (1.0 ) Long-lived asset impairments (0.6 ) 0.7 (0.6 ) 1.9 Other — 0.1 — 0.3 Other charges, net $ 2.1 $ 4.2 $ 9.5 $ 12.2 Restructuring Initiatives Restructuring charges Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 0.2 $ 0.2 $ 1.5 $ 1.3 Other charges, net 0.9 1.7 3.6 4.4 $ 1.6 $ 1.9 $ 5.1 $ 5.7 The following table sets forth the changes in restructuring reserves (dollars in millions): Total Severance Exit Costs Provisions Balance at December 31, 2020 $ 9.8 $ 7.6 $ 0.8 $ 1.4 Restructuring charges 5.1 4.1 1.0 — Cash payments (9.7 ) (9.0 ) (0.7 ) — Other, non-cash (0.8 ) — (0.7 ) (0.1 ) Balance at September 30, 2021 $ 4.4 $ 2.7 $ 0.4 $ 1.3

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments And Contingencies
Commitments and Contingencies	14. Commitments and Contingencies In accordance with ASC Topic 450, Contingencies, the Company accrues anticipated costs of settlement, damages or other costs to the extent specific losses are probable and estimable. Litigation and Related Contingencies Lawsuits, claims and proceedings of a nature considered normal to its businesses may be pending from time to time against the Company. Third parties might allege that the Company or its collaborators are infringing their patent rights or that the Company is otherwise violating their intellectual property rights. Loss contingency provisions are recorded if the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount can be reasonably estimated or a range of loss can be determined. These accruals represent management’s best estimate of probable loss. Disclosure is also provided when it is reasonably possible that a loss will be incurred or when it is reasonably possible that the amount of a loss will exceed the recorded provision. The Company believes the outcome of pending proceedings, individually and in the aggregate, will not have a material impact on the Company’s financial statements. On September 25, 2019, in a complaint filed in the Düsseldorf, Germany, District Court, Carl Zeiss Microscopy GmbH, a subsidiary of Carl Zeiss AG (Zeiss), sued Luxendo GmbH (Luxendo), a subsidiary of Bruker Corporation, for infringement of a recently registered German utility model patent licensed to Zeiss pertaining to one specific Luxendo product category. The Company is vigorously defending against this claim. As of September 30, 2021 and December 31, 2020, no material accruals have been recorded for potential contingencies.

Business Segment Information

Business Segment Information	9 Months Ended
	Sep. 30, 2021
Business Segment Information
Business Segment Information	15. Business Segment Information The Company has three reportable segments, BSI Life Science, BSI NANO and BEST, as discussed in Note 1 to the unaudited condensed consolidated financial statements. Revenue and operating income by reportable segment are presented below (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenue: BSI Life Science $ 380.7 $ 323.4 $ 1,074.3 $ 842.6 BSI NANO 174.9 147.1 504.6 392.7 BEST 57.0 43.8 166.0 134.8 Eliminations (a) (3.7 ) (2.9 ) (10.5 ) (10.1 ) Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Operating Income (loss) BSI Life Science $ 100.9 $ 80.6 $ 263.4 $ 158.7 BSI NANO 21.8 12.2 55.1 9.3 BEST 7.4 1.2 18.3 5.1 Corporate, eliminations and other (b) (16.9 ) (12.8 ) (48.9 ) (37.6 ) Total operating income $ 113.2 $ 81.2 $ 287.9 $ 135.5 (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. Total assets by reportable segment are as follows (dollars in millions): September 30, December 31, Assets: BSI Life Science, BSI NANO & Corporate $ 3,038.8 $ 2,964.5 BEST 95.1 88.7 Eliminations and other (a) (6.2 ) (4.2 ) Total assets $ 3,127.7 $ 3,049.0 (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions. The Company is unable, without unreasonable effort or expense to disclose the amount of total assets by BSI Life Science and BSI NANO segments as well as the Corporate function and further, the Company’s chief operating decision maker does not receive any asset information by operating segment.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue
Schedule of revenues disaggregated by Group, end customer geographical location and timing of recognition	The following table presents the Company’s revenues by Group and End Customer Geography (dollars in millions): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue by Group: Bruker BioSpin $ 186.5 $ 152.1 $ 494.4 $ 398.1 Bruker CALID 194.2 171.3 579.9 444.5 Bruker Nano 174.9 147.1 504.6 392.7 BEST 57.0 43.8 166.0 134.8 Eliminations (3.7 ) (2.9 ) (10.5 ) (10.1 ) Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue by End Customer Geography: United States $ 163.2 $ 120.1 $ 442.0 $ 332.1 Germany 55.5 50.4 186.4 134.9 Rest of Europe 155.4 142.9 459.9 357.7 Asia Pacific 191.6 160.0 525.8 433.3 Other 43.2 38.0 120.3 102.0 Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Revenue for the Company recognized at a point in time versus over time is as follows (dollars in millions): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Revenue recognized at a point in time $ 530.8 $ 442.2 $ 1,503.0 $ 1,174.0 Revenue recognized over time 78.1 69.2 231.4 186.0 Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
2021 Acquisitions
Acquisitions
Schedule of components and fair value allocation of the consideration transferred in connection with acquisitions	The following table reflects the consideration transferred and the respective reportable segment for the acquisitions (in millions): Name of Acquisition Date Acquired Segment Total Cash Creative Instruments July 1, 2021 BSI Life Science $ 1.0 $ 1.0 SVXR, Inc. September 9, 2021 BSI Nano 14.0 11.9 $ 15.0 $ 12.9 Name Acquisition / Date Acquired Segment Consideration Cash Glycopath Inc. Investment February 18, 2021 BSI Life Science $ 2.0 $ 2.0 IonPath Inc. Investment March 18, 2021 BSI Life Science 2.0 2.0 Olaris, Inc. Investment September 23, 2021 BSI Life Science 0.5 0.5 $ 4.5 $ 4.5
SCI Instruments
Acquisitions
Schedule of consideration transferred and the respective reporting segment for each acquisition	The acquisition is being accounted for under the acquisition method. The components and fair value allocation of the consideration transferred in connection with the acquisition are as follows (dollars in millions): Consideration Transferred: Cash paid $ 28.0 Fair value of contingent consideration 1.0 Working capital adjustment (1.0 ) Total consideration transferred $ 28.0 Allocation of Consideration Transferred: Inventories $ 1.0 Other current and non-current 1.0 Intangible assets: Technology 7.1 Customer relationships 6.4 Trade name 0.4 Backlog 1.2 Goodwill 12.6 Liabilities assumed (1.7 ) Total consideration allocated $ 28.0

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventories
Schedule of inventories	Inventories consisted of the following (dollars in millions): September 30, December 31, Raw materials $ 209.9 $ 198.8 Work-in-process 272.5 245.7 Finished goods 155.9 152.1 Demonstration units 94.5 95.7 Inventories $ 732.8 $ 692.3

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Goodwill and Intangible Assets
Schedule of changes in the carrying amount of goodwill	The following table sets forth the changes in the carrying amount of goodwill (dollars in millions): Total Balance at December 31, 2020 $ 320.4 Current period additions/adjustments 12.7 Foreign currency impact (8.9 ) Balance at September 30, 2021 $ 324.2
Summary of intangible assets	The following is a summary of intangible assets, excluding goodwill (dollars in millions): September 30, 2021 December 31, 2020 Gross Accumulated Net Carrying Gross Accumulated Net Carrying Existing technology and related patents $ 308.4 $ (202.1 ) $ 106.3 $ 309.8 $ (194.6 ) $ 115.2 Customer relationships 155.1 (54.6 ) 100.5 148.3 (45.4 ) 102.9 Trade names 15.1 (5.4 ) 9.7 15.2 (4.4 ) 10.8 Other 1.8 (0.6 ) 1.2 0.3 (0.1 ) 0.2 Intangible assets $ 480.4 $ (262.7 ) $ 217.7 $ 473.6 $ (244.5 ) $ 229.1

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2021
Debt
Components of debt obligations	The Company’s debt obligations consisted of the following (dollars in millions): September 30, December 31, US Dollar notes under the 2012 Note Purchase Agreement $ 205.0 $ 205.0 CHF notes (in dollars) under the 2019 Note Purchase Agreement 318.1 335.5 US Dollar notes under the 2019 Term Loan 300.0 300.0 Unamortized debt issuance costs (2.1 ) (2.4 ) Finance lease obligations and other loans 6.0 6.4 Total debt 827.0 844.5 Current portion of long-term debt (109.5 ) (2.2 ) Total long-term debt, less current portion $ 717.5 $ 842.3
Summary of maximum commitments and net amounts available under the 2019 Credit Agreement and other lines of credit	The following is a summary of the maximum commitments and the net amounts available to the Company under its credit agreements and other lines of credit with various financial institutions located primarily in Germany and Switzerland that are unsecured and typically due upon demand with interest payable monthly, at September 30, 2021 (in millions): Weighted Total Amount Outstanding Outstanding Total 2019 Credit Agreement 1.3 % $ 600.0 $ — $ 0.1 $ 599.9 Bank guarantees and working capital line varies 115.2 — 115.2 — Total revolving lines of credit $ 715.2 $ — $ 115.3 $ 599.9

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value of Financial Instruments
Schedule of financial instruments measured at fair value on a recurring basis	The following tables set forth the Company’s financial instruments measured at fair value on a recurring basis and present them within the fair value hierarchy using the lowest level of input that is significant to the fair value measurement (dollars in millions): September 30, 2021 Total Quoted Prices Significant Significant Assets: Time deposits and money market funds $ 12.4 $ — $ 12.4 $ — Short-term investments 96.8 — 96.8 — Interest rate and cross currency swap agreements 7.1 — 7.1 — Fixed price commodity contracts 0.8 — 0.8 — Debt securities available for sale 1.2 — — 1.2 Total assets recorded at fair value $ 118.3 $ — $ 117.1 $ 1.2 Liabilities: Contingent consideration $ 5.6 $ — $ — $ 5.6 Hybrid instrument liability 14.3 — — 14.3 Interest rate and cross currency swap agreements 29.0 — 29.0 — Embedded derivatives in purchase and delivery contracts 0.1 — 0.1 — Forward currency contracts 0.7 — 0.7 — Long-term fixed interest rate debt 535.1 — 535.1 — Total liabilities recorded at fair value $ 584.8 $ — $ 564.9 $ 19.9 December 31, 2020 Total Quoted Prices Significant Significant Assets: Time deposits and money market funds $ 183.2 $ — $ 183.2 $ — Short-term investments 50.0 — 50.0 — Interest rate and cross currency swap agreements 7.6 — 7.6 — Forward currency contracts 2.1 — 2.1 — Embedded derivatives in purchase and delivery contracts 0.1 — 0.1 — Fixed price commodity contracts 3.1 — 3.1 — Debt securities available for sale 1.2 — — 1.2 Total assets recorded at fair value $ 247.3 $ — $ 246.1 $ 1.2 Liabilities: Contingent consideration $ 4.3 $ — $ — $ 4.3 Hybrid instrument liability 13.9 — — 13.9 Interest rate and cross currency swap agreements 61.5 — 61.5 — Forward currency contracts 0.4 — 0.4 — Long-term fixed interest rate debt 549.8 — 549.8 — Total liabilities recorded at fair value $ 629.9 $ — $ 611.7 $ 18.2
Schedule of changes in contingent consideration liabilities	The following table sets forth the changes in contingent consideration liabilities (dollars in millions): Balance at December 31, 2020 $ 4.3 Current period additions 1.9 Current period adjustments (0.1 ) Current period settlements (0.4 ) Foreign currency effect (0.1 ) Balance at September 30, 2021 $ 5.6
Schedule of changes in hybrid instrument liability	The following table sets forth the changes in hybrid instrument liability (dollars in millions): Balance at December 31, 2020 $ 13.9 Current period adjustments 1.1 Foreign currency effect (0.7 ) Balance at September 30, 2021 $ 14.3

Derivative Instruments and He_2

Derivative Instruments and Hedging Activities (Tables)	9 Months Ended
	Sep. 30, 2021
Derivative Instruments and Hedging Activities
Schedule of notional amounts outstanding under foreign currency contracts	The Company had notional amounts outstanding under forward currency contracts and cross-currency interest rate swap agreements as of (dollars in millions): September 30, 2021 December 31, 2020 Notional Fair Value Notional Fair Value Forward currency contracts (1): Assets $ 10.4 $ — $ 175.8 $ 2.1 Liabilities 114.1 (0.7 ) 102.5 (0.4 ) Cross-currency and interest rate swap agreements (2): Liabilities 505.0 (21.9 ) 505.0 (53.9 ) Long-term debt Liabilities 318.1 (20.2 ) 335.5 (37.6 ) Total $ 947.6 $ (42.8 ) $ 1,118.8 $ (89.8 ) (1) Derivatives not designated as accounting hedges. (2) Derivatives designated as accounting hedges.
Schedule of fair value and balance sheet location of derivative instruments	The derivative instruments described above are recorded in the unaudited condensed consolidated balance sheets for the periods ended as follows (dollars in millions): September 30, 2021 December 31, 2020 Derivatives designated as hedging instruments Interest rate cross-currency swap agreements Other current assets $ 7.1 $ 7.6 Other current liabilities (8.5 ) (4.3 ) Other long-term liabilities (20.5 ) (57.2 ) (21.9 ) (53.9 ) Long-term debt Long-term debt (20.2 ) (37.6 ) Total derivatives designated as hedging instruments $ (42.1 ) $ (91.5 ) Derivatives not designated as hedging instruments Forward currency contracts Other current assets $ — $ 2.1 Other current liabilities (0.7 ) (0.4 ) Embedded derivatives in purchase and delivery contracts Other current assets — 0.1 Other current liabilities (0.1 ) — Fixed price commodity contracts Other current assets 0.8 3.1 Total derivatives not designated as hedging instruments — 4.9 Total derivatives $ (42.1 ) $ (86.6 )
Schedule of impact on net income of unrealized gains and losses resulting from changes in the fair value of derivative instruments	The following is a summary of the activity included in the unaudited condensed consolidated statements of income and comprehensive income related to the derivative instruments described above (in millions): Location of gain (loss) recognized in income on derivative Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Derivatives not designated as hedging instruments Forward currency contracts Interest and other income (expense), net $ (0.9 ) $ (0.2 ) $ (4.8 ) $ (0.4 ) Embedded Interest and other income (expense), net 0.1 (0.1 ) (0.3 ) 0.8 (0.8 ) (0.3 ) (5.1 ) 0.4 Derivatives designated as cash flow hedging instruments Interest rate cross-currency swap agreements Interest and other income (expense), net $ (1.2 ) $ (1.1 ) $ (3.5 ) $ (1.9 ) Derivatives designated as net investment hedging instruments Interest rate cross-currency swap agreements Interest and other income (expense), net 2.6 2.5 7.6 7.7 1.4 1.4 4.1 5.8 Total $ 0.6 $ 1.1 $ (1.0 ) $ 6.2 Amount of unrealized gain (loss) on contracts recognized other comprehensive income (loss) Three Months Ended September 30, Nine Months Ended September 30, Financial Statement Classification 2021 2020 2021 2020 Derivatives designated as cash flow hedging instruments Interest rate cross-currency Accumulated other comprehensive income, net of tax $ 0.9 $ (0.2 ) $ 11.5 $ (22.1 ) $ 0.9 $ (0.2 ) $ 11.5 $ (22.1 ) Derivatives designated as net investment hedging instruments Interest rate cross-currency swap agreements Accumulated other comprehensive income, net of tax $ 7.4 $ (21.9 ) $ 25.6 $ (0.3 ) Long-term debt Accumulated other comprehensive income, net of tax 2.2 (8.2 ) 22.2 (15.3 ) $ 9.6 $ (30.1 ) $ 47.8 $ (15.6 ) Total $ 10.5 $ (30.3 ) $ 59.3 $ (37.7 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share
Computation of basic and diluted weighted average shares outstanding and net income per common share	The following table sets forth the computation of basic and diluted weighted average shares outstanding and net income per common share attributable to Bruker shareholders (dollars in millions, except per share amounts): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Net income attributable to Bruker Corporation, as reported $ 87.1 $ 54.3 $ 201.4 $ 88.9 Weighted average shares outstanding: Weighted average shares outstanding-basic 151.4 153.2 151.5 153.7 Effect of dilutive securities: Stock options and restricted stock awards and units 1.4 1.1 1.5 1.1 152.8 154.3 153.0 154.8 Net income per common share attributable to Bruker Corporation shareholders: Basic $ 0.58 $ 0.35 $ 1.33 $ 0.58 Diluted $ 0.57 $ 0.35 $ 1.32 $ 0.57
Schedule of common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive	The following common share equivalents have been excluded from the computation of diluted weighted-average shares outstanding, as their effect would have been anti-dilutive (amounts in millions of shares): Three Months Ended Nine Months Ended 2021 2020 2021 2020 Stock options — 0.3 — 0.1 Unvested restricted stock units — 0.2 — 0.1

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Shareholders' Equity
Summary of comprehensive income (loss)	The following is a summary of comprehensive income (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Consolidated net income $ 88.1 $ 55.3 $ 204.6 $ 90.1 Foreign currency translation adjustments (26.6 ) 38.9 (80.2 ) 42.8 Derivatives designated as hedging instruments, net of tax 10.5 (30.3 ) 59.3 (37.7 ) Pension liability adjustments, net of tax 1.1 0.1 4.4 14.9 Net comprehensive income 73.1 64.0 188.1 110.1 Less: Comprehensive income attributable to noncontrolling interests 0.7 1.4 0.9 1.5 Less: Comprehensive loss attributable to redeemable noncontrolling interest — — — (0.5 ) Comprehensive income attributable to Bruker Corporation $ 72.4 $ 62.6 $ 187.2 $ 109.1
Summary of the components of accumulated other comprehensive income (loss), net of tax	The following is a summary of the components of Foreign Derivatives Pension Accumulated Balance at December 31, 2020 $ 140.9 $ (91.5 ) $ (45.7 ) $ 3.7 Other comprehensive (loss) income before reclassifications, net of tax (78.1 ) 59.3 2.2 (16.6 ) Realized loss on amounts reclassified from other comprehensive income, net of tax — — 2.2 2.2 Net current period other comprehensive (loss) income (78.1 ) 59.3 4.4 (14.4 ) Balance at September 30, 2021 $ 62.8 $ (32.2 ) $ (41.3 ) $ (10.7 )
Schedule of the impact of stock-based compensation expense	The Company recorded stock-based compensation expense as follows in the unaudited condensed consolidated statements of income and comprehensive income (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Costs of product revenue $ 0.6 $ 0.6 $ 1.6 $ 1.5 Selling, general and administrative 2.6 2.9 7.6 6.9 Research and development 0.6 0.6 1.6 1.5 Total stock-based compensation $ 3.8 $ 4.1 $ 10.8 $ 9.9
Schedule of stock option activity	Stock option activity was as follows: Shares Subject Weighted Weighted Aggregate Outstanding at December 31, 2020 1,856,176 $ 25.32 Granted 79,632 $ 85.10 Exercised (515,692 ) $ 20.40 Forfeited/Expired — $ — Outstanding at September 30, 2021 1,420,116 $ 30.45 4.3 $ 68.2 Exercisable at September 30, 2021 1,158,452 $ 24.66 3.8 $ 61.9 Exercisable and expected to vest at September 30, 2021 (a) 1,384,099 $ 29.68 4.2 $ 67.5 (a) Represents the number of vested options at September 30, 2021, plus the number of unvested options at September 30, 2021 that are ultimately expected to vest based on our estimated forfeiture rate. (b) The aggregate intrinsic value is based on the positive difference between the exercise price of the underlying options and the quoted price of our common stock on September 30, 2021. The total intrinsic value of options exercised was $31.8 million and $2.2 million for the nine months ended September 30, 2021 and 2020, respectively.
Schedule of Unvested restricted stock unit activity	Restricted stock unit activity was as follows: Shares Subject Weighted Outstanding at December 31, 2020 805,052 $ 39.63 Granted 216,692 $ 78.01 Vested (329,840 ) $ 37.07 Forfeited (19,043 ) $ 43.52 Outstanding at September 30, 2021 672,861 $ 53.14
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions	Nine months ended September 30, 2021 2020 Risk-free interest rates 0.62 % 0.23 % Expected life 4.43 years 5.14 years Volatility 34 % 34 % Expected dividend yield 0.20 % 0.37 %

Other Charges, Net (Tables)

Other Charges, Net (Tables)	9 Months Ended
	Sep. 30, 2021
Other Charges (Gain), Net
Schedule of components of other charges, net	The components of other charges, net were as Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Information technology transformation costs $ 1.1 $ 0.5 $ 2.6 $ 1.8 Professional fees incurred in connection with investigation matters 0.1 0.3 0.1 4.8 Restructuring charges 0.9 1.7 3.6 4.4 Acquisition-related charges 0.6 0.9 3.8 (1.0 ) Long-lived asset impairments (0.6 ) 0.7 (0.6 ) 1.9 Other — 0.1 — 0.3 Other charges, net $ 2.1 $ 4.2 $ 9.5 $ 12.2
Summary of restructuring charges	The following table sets forth the restructuring charges (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Cost of revenues $ 0.2 $ 0.2 $ 1.5 $ 1.3 Other charges, net 0.9 1.7 3.6 4.4 $ 1.6 $ 1.9 $ 5.1 $ 5.7
Schedule of changes in restructuring reserves	The following table sets forth the changes in restructuring reserves (dollars in millions): Total Severance Exit Costs Provisions Balance at December 31, 2020 $ 9.8 $ 7.6 $ 0.8 $ 1.4 Restructuring charges 5.1 4.1 1.0 — Cash payments (9.7 ) (9.0 ) (0.7 ) — Other, non-cash (0.8 ) — (0.7 ) (0.1 ) Balance at September 30, 2021 $ 4.4 $ 2.7 $ 0.4 $ 1.3

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Sep. 30, 2021
Business Segment Information
Schedule of revenue, operating income and total assets by reportable segment	Revenue and operating income by reportable segment are presented below (dollars in millions): Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Revenue: BSI Life Science $ 380.7 $ 323.4 $ 1,074.3 $ 842.6 BSI NANO 174.9 147.1 504.6 392.7 BEST 57.0 43.8 166.0 134.8 Eliminations (a) (3.7 ) (2.9 ) (10.5 ) (10.1 ) Total revenue $ 608.9 $ 511.4 $ 1,734.4 $ 1,360.0 Operating Income (loss) BSI Life Science $ 100.9 $ 80.6 $ 263.4 $ 158.7 BSI NANO 21.8 12.2 55.1 9.3 BEST 7.4 1.2 18.3 5.1 Corporate, eliminations and other (b) (16.9 ) (12.8 ) (48.9 ) (37.6 ) Total operating income $ 113.2 $ 81.2 $ 287.9 $ 135.5 (a) Represents product and service revenue between reportable segments. (b) Represents corporate costs and eliminations not allocated to the reportable segments. Total assets by reportable segment are as follows (dollars in millions): September 30, December 31, Assets: BSI Life Science, BSI NANO & Corporate $ 3,038.8 $ 2,964.5 BEST 95.1 88.7 Eliminations and other (a) (6.2 ) (4.2 ) Total assets $ 3,127.7 $ 3,049.0 (a) Assets not allocated to the reportable segments and eliminations of intercompany transactions.

Description of Business (Detail

Description of Business (Details)	9 Months Ended
	Sep. 30, 2021segment
Description of Business
Number of operating segments	4
Number of reportable segments	3

Revenue - Disaggregation (Detai

Revenue - Disaggregation (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues disaggregated by Group
Total revenue	$ 608.9	$ 511.4	$ 1,734.4	$ 1,360
Revenue recognized at a point in time
Revenues disaggregated by Group
Total revenue	530.8	442.2	1,503	1,174
Revenue recognized over time
Revenues disaggregated by Group
Total revenue	78.1	69.2	231.4	186
United States
Revenues disaggregated by Group
Total revenue	163.2	120.1	442	332.1
Germany
Revenues disaggregated by Group
Total revenue	55.5	50.4	186.4	134.9
Rest of Europe
Revenues disaggregated by Group
Total revenue	155.4	142.9	459.9	357.7
Asia Pacific
Revenues disaggregated by Group
Total revenue	191.6	160	525.8	433.3
Other
Revenues disaggregated by Group
Total revenue	43.2	38	120.3	102
Bruker BioSpin
Revenues disaggregated by Group
Total revenue	186.5	152.1	494.4	398.1
Bruker CALID
Revenues disaggregated by Group
Total revenue	194.2	171.3	579.9	444.5
Bruker Nano
Revenues disaggregated by Group
Total revenue	174.9	147.1	504.6	392.7
BEST
Revenues disaggregated by Group
Total revenue	57	43.8	166	134.8
Eliminations
Revenues disaggregated by Group
Total revenue	$ (3.7)	$ (2.9)	$ (10.5)	$ (10.1)

Revenue - Remaining Performance

Revenue - Remaining Performance Obligations (Details) $ in Millions	Sep. 30, 2021USD ($)
Remaining Performance Obligations
Amount of remaining performance obligations	$ 2,035.9
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01
Remaining Performance Obligations
Remaining performance obligation expected to be recognized in the given period (as a percent)	68.40%
Duration of expected recognition period for remaining performance obligation	12 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Minimum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-01-01 | Maximum
Remaining Performance Obligations
Duration of expected recognition period for remaining performance obligation	3 years

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Revenue
Contract assets	$ 56.4	$ 41.8
Contract liabilities	400.6	$ 399.4
Revenue recognition during the period	$ 250.5

Acquisitions - SCI Instruments

Acquisitions - SCI Instruments (Details) - USD ($) $ in Millions	Aug. 24, 2021	Sep. 30, 2021	Dec. 31, 2020
Allocation of Consideration Transferred:
Goodwill		$ 324.2	$ 320.4
SCI Instruments
Consideration Transferred:
Contingent consideration	$ 1
Allocation of Consideration Transferred:
Purchase price	28
Potential additional consideration	$ 4
Amortization period for intangible assets acquired	10 years
SCI Instruments | Technology
Allocation of Consideration Transferred:
Amortization period for intangible assets acquired	10 years
SCI Instruments | Customer relationships
Allocation of Consideration Transferred:
Amortization period for intangible assets acquired	9 years
SCI Instruments | BSI NANO
Consideration Transferred:
Cash paid	$ 28
Fair value of contingent consideration	1
Working capital adjustment	(1)
Cash acquired	28
Allocation of Consideration Transferred:
Inventories	1
Other current and non-current assets	1
Goodwill	12.6
Liabilities assumed	(1.7)
Total consideration transferred	28
SCI Instruments | BSI NANO | Technology
Allocation of Consideration Transferred:
Intangible assets	7.1
SCI Instruments | BSI NANO | Customer relationships
Allocation of Consideration Transferred:
Intangible assets	6.4
SCI Instruments | BSI NANO | Backlog
Allocation of Consideration Transferred:
Intangible assets	1.2
SCI Instruments | BSI NANO | Trade name
Allocation of Consideration Transferred:
Intangible assets	$ 0.4

Acquisitions - Consideration tr

Acquisitions - Consideration transferred and reportable segment (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Business Acquisition [Line Items]
Cash Consideration	$ 45	$ 58.8
Investments in Businesses [Member]
Business Acquisition [Line Items]
Consideration	4.5
Cash Consideration	4.5
Creative Instruments | BSI Life Science
Business Acquisition [Line Items]
Consideration	1
Cash Consideration	1
SVXR, Inc. | BSI NANO
Business Acquisition [Line Items]
Consideration	14
Cash Consideration	11.9
Glycopath Inc. | BSI Life Science | Investments in Businesses [Member]
Business Acquisition [Line Items]
Consideration	2
Cash Consideration	2
IonPath Inc | BSI Life Science | Investments in Businesses [Member]
Business Acquisition [Line Items]
Consideration	2
Cash Consideration	2
Olaris, Inc. | BSI Life Science | Investments in Businesses [Member]
Business Acquisition [Line Items]
Consideration	0.5
Cash Consideration	0.5
Acquisitions in 2021
Business Acquisition [Line Items]
Consideration	15
Cash Consideration	$ 12.9

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Inventories
Raw materials	$ 209.9	$ 198.8
Work-in-process	272.5	245.7
Finished goods	155.9	152.1
Demonstration units	94.5	95.7
Inventories	732.8	692.3
Inventory-in-transit	$ 53.9	$ 67.8

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Goodwill
Balance at the beginning of the period	$ 320.4
Current period additions/adjustments	12.7
Foreign currency impact	(8.9)
Balance at the end of the period	$ 324.2

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	$ 480.4		$ 480.4		$ 473.6
Accumulated Amortization, intangible assets subject to amortization	(262.7)		(262.7)		(244.5)
Net Carrying Amount, intangible assets subject to amortization	217.7		217.7		229.1
Amortization expense related to intangible assets subject to amortization	9.3	$ 9	27.3	$ 26.7
Technology
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	308.4		308.4		309.8
Accumulated Amortization, intangible assets subject to amortization	(202.1)		(202.1)		(194.6)
Net Carrying Amount, intangible assets subject to amortization	106.3		106.3		115.2
Customer relationships
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	155.1		155.1		148.3
Accumulated Amortization, intangible assets subject to amortization	(54.6)		(54.6)		(45.4)
Net Carrying Amount, intangible assets subject to amortization	100.5		100.5		102.9
Trade name
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	15.1		15.1		15.2
Accumulated Amortization, intangible assets subject to amortization	(5.4)		(5.4)		(4.4)
Net Carrying Amount, intangible assets subject to amortization	9.7		9.7		10.8
Other
Intangible assets
Gross Carrying Amount, intangible assets subject to amortization	1.8		1.8		0.3
Accumulated Amortization, intangible assets subject to amortization	(0.6)		(0.6)		(0.1)
Net Carrying Amount, intangible assets subject to amortization	$ 1.2		$ 1.2		$ 0.2

Debt - Components (Details)

Debt - Components (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Debt
Unamortized debt issuance costs	$ (2.1)	$ (2.4)
Total debt	827	844.5
Current portion of long-term debt	(109.5)	(2.2)
Total long-term debt, less current portion	717.5	842.3
2012 Note Purchase Agreement
Debt
Debt, before unamortized debt issuance costs	205	205
2019 Note Purchase Agreement
Debt
Debt, before unamortized debt issuance costs	318.1	335.5
2019 Term Loan
Debt
Debt, before unamortized debt issuance costs	300	300
Finance lease obligations and other loans
Debt
Total debt	$ 6	$ 6.4

Debt - Revolving Loan Arrangeme

Debt - Revolving Loan Arrangements (Details) $ in Millions	Sep. 30, 2021USD ($)
Revolving lines of credit
Total Amount Committed by Lenders	$ 715.2
Outstanding Letters of Credit	115.3
Total Committed Amount Available	$ 599.9
2019 Credit Agreement | US Dollar revolving loan
Revolving lines of credit
Weighted Average Interest Rate (as a percent)	1.30%
Total Amount Committed by Lenders	$ 600
Outstanding Letters of Credit	0.1
Total Committed Amount Available	599.9
Bank guarantees and working capital line
Revolving lines of credit
Total Amount Committed by Lenders	115.2
Outstanding Letters of Credit	$ 115.2

Debt - Currency Swaps (Details)

Debt - Currency Swaps (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Debt
Reduction of interest expense by cross-currency and interest swap agreements	$ 1.4	$ 1.4	$ 4.1	$ 5.8
US to Swiss Franc
Debt
Notional Amount	150		150
US to Euro
Debt
Notional Amount	$ 355		$ 355

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Hierarchy (Details) - Recurring basis - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Assets:
Time deposits and money market funds	$ 12.4	$ 183.2
Short-term investments	96.8	50
Interest rate and cross currency swap agreements	7.1	7.6
Forward currency contracts		2.1
Embedded derivatives in purchase and delivery contracts		0.1
Fixed price commodity contracts	0.8	3.1
Debt securities available for sale	1.2	1.2
Total assets recorded at fair value	118.3	247.3
Liabilities:
Contingent consideration	5.6	4.3
Hybrid instrument liability	14.3	13.9
Interest rate and cross currency swap agreements	29	61.5
Embedded derivatives in purchase and delivery contracts	0.1
Forward currency contracts	0.7	0.4
Long-term fixed interest rate debt	535.1	549.8
Total liabilities recorded at fair value	584.8	629.9
Significant Other Observable Inputs (Level 2)
Assets:
Time deposits and money market funds	12.4	183.2
Short-term investments	96.8	50
Interest rate and cross currency swap agreements	7.1	7.6
Forward currency contracts		2.1
Embedded derivatives in purchase and delivery contracts		0.1
Fixed price commodity contracts	0.8	3.1
Total assets recorded at fair value	117.1	246.1
Liabilities:
Interest rate and cross currency swap agreements	29	61.5
Embedded derivatives in purchase and delivery contracts	0.1
Forward currency contracts	0.7	0.4
Long-term fixed interest rate debt	535.1	549.8
Total liabilities recorded at fair value	564.9	611.7
Significant Unobservable Inputs (Level 3)
Assets:
Debt securities available for sale	1.2	1.2
Total assets recorded at fair value	1.2	1.2
Liabilities:
Contingent consideration	5.6	4.3
Hybrid instrument liability	14.3	13.9
Total liabilities recorded at fair value	$ 19.9	$ 18.2

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Contingent Consideration and Hybrid Instrument Liability (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Mestrelab
Fair value of financial instruments
Remaining ownership percentage under options that can be exercised after 2022	49.00%
Contingent consideration
Changes in contingent consideration liabilities
Balance at December 31, 2020	$ 4.3
Current period additions	1.9
Current period adjustments	(0.1)
Current period settlements	(0.4)
Foreign currency effect	(0.1)
Balance at September 30, 2021	5.6
Hybrid instrument
Changes in contingent consideration liabilities
Balance at December 31, 2020	13.9
Current period adjustments	1.1
Foreign currency effect	(0.7)
Balance at September 30, 2021	$ 14.3

Derivative Instruments and He_3

Derivative Instruments and Hedging Activities - Risk Management (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Derivative instruments and hedging activities
Fair value, net asset (liability)	$ (42.1)	$ (86.6)
Embedded derivatives in purchase and delivery contracts
Embedded derivatives in purchase and delivery contracts
Notional amount of derivative sale contracts	6	7.5
Notional amount of derivative purchase contracts	7	4.8
Forward currency and swap agreements
Derivative instruments and hedging activities
Notional Amount	947.6	1,118.8
Fair value, net asset (liability)	(42.8)	(89.8)
Forward currency contract
Derivative instruments and hedging activities
Notional amount, assets	10.4	175.8
Notional amount, liabilities	114.1	102.5
Not designated as accounting hedges
Assets		2.1
Liabilities	(0.7)	(0.4)
Fixed price commodity contracts
Derivative instruments and hedging activities
Notional Amount	4.5	8.8
Interest rate cross-currency swap agreements
Derivative instruments and hedging activities
Notional amount, liabilities	505	505
Designated as accounting hedges
Liabilities	(21.9)	(53.9)
Long-term debt
Derivative instruments and hedging activities
Notional amount, liabilities	318.1	335.5
Not designated as accounting hedges
Liabilities	$ (20.2)	$ (37.6)

Derivative Instruments and He_4

Derivative Instruments and Hedging Activities - Balance Sheet (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	$ (42.1)	$ (86.6)
Forward currency and swap agreements
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(42.8)	(89.8)
Embedded derivatives in purchase and delivery contracts | Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(0.1)
Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(21.9)	(53.9)
Designated as hedging instrument
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(42.1)	(91.5)
Designated as hedging instrument | Other current assets
Derivative instruments and hedging activities
Derivative Asset	7.1	7.6
Designated as hedging instrument | Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(8.5)	(4.3)
Designated as hedging instrument | Other long-term liabilities
Derivative instruments and hedging activities
Derivative Liability	(20.5)	(57.2)
Designated as hedging instrument | Long-term debt
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	(20.2)	(37.6)
Not designated as hedging instruments
Derivative instruments and hedging activities
Derivative Assets (Liabilities)	0	4.9
Not designated as hedging instruments | Forward currency contract | Other current assets
Derivative instruments and hedging activities
Derivative Asset		2.1
Not designated as hedging instruments | Forward currency contract | Other current liabilities
Derivative instruments and hedging activities
Derivative Liability	(0.7)	(0.4)
Not designated as hedging instruments | Embedded derivatives in purchase and delivery contracts | Other current assets
Derivative instruments and hedging activities
Derivative Asset		0.1
Not designated as hedging instruments | Fixed price commodity contracts | Other current assets
Derivative instruments and hedging activities
Derivative Asset	$ 0.8	$ 3.1

Derivative Instruments and He_5

Derivative Instruments and Hedging Activities - Income and Comprehensive Income Statement (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Not designated as hedging instruments
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	$ (0.8)	$ (0.3)	$ (5.1)	$ 0.4
Not designated as hedging instruments | Interest and other income (expense), net | Forward currency contract
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	(0.9)	(0.2)	(4.8)	(0.4)
Not designated as hedging instruments | Interest and other income (expense), net | Embedded derivatives in purchase and delivery contracts
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	0.1	(0.1)	(0.3)	0.8
Not designated as hedging instruments | Net Investment Hedging | Accumulated other comprehensive income, net of tax
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	10.5	30.3	59.3	37.7
Not designated as hedging instruments | Net Investment Hedging | Accumulated other comprehensive income, net of tax | Accumulated other comprehensive income
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	9.6	(30.1)	47.8	15.6
Designated as hedging instrument | Cash Flow Hedging | Interest and other income (expense), net | Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	(1.2)	(1.1)	(3.5)	(1.9)
Designated as hedging instrument | Cash Flow Hedging | Accumulated other comprehensive income, net of tax
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	0.9	0.2	11.5	22.1
Designated as hedging instrument | Cash Flow Hedging | Accumulated other comprehensive income, net of tax | Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	0.9	(0.2)	11.5	(22.1)
Designated as hedging instrument | Net Investment Hedging
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	0.6	1.1	(1)	6.2
Designated as hedging instrument | Net Investment Hedging | Accumulated other comprehensive income | Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	1.4	1.4	4.1	5.8
Designated as hedging instrument | Net Investment Hedging | Interest and other income (expense), net | Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	2.6	2.5	7.6	7.7
Designated as hedging instrument | Net Investment Hedging | Accumulated other comprehensive income, net of tax | Interest rate and cross currency swap agreements
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	7.4	(21.9)	25.6	(0.3)
Designated as hedging instrument | Net Investment Hedging | Accumulated other comprehensive income, net of tax | Long-term debt
Derivative instruments and hedging activities
Impact on net income of unrealized gains and losses	$ 2.2	$ 8.2	$ 22.2	$ 15.3

Provision for Income Taxes (Det

Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Provision for Income Taxes
Income tax expense (benefit)	$ 20.7	$ 20	$ 69.5	$ 30
Effective tax rates (as a percent)	19.00%	26.60%	25.40%	25.00%
Unrecognized tax benefits, excluding penalties and interest	$ 34.8		$ 34.8		$ 22.7
Accrued interest and penalties related to uncertain tax positions	2.3		2.3		$ 1.8
Penalties and interest (benefit) expense relating to unrecognized tax benefits	$ 0.2	$ 0.1	$ 0.6	$ 0.4
Statutory tax rate (as a percent)			21.00%
Change in tax rate - foreign jurisdictions (as a percent)			5.50%
Germany
Provision for Income Taxes
Statutory tax rate (as a percent)			30.00%
Switzerland
Provision for Income Taxes
Statutory tax rate (as a percent)			20.00%

Earnings Per Share - Computatio

Earnings Per Share - Computation (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share
Net income attributable to Bruker Corporation, as reported	$ 87.1	$ 54.3	$ 201.4	$ 88.9
Weighted average shares outstanding:
Weighted average shares outstanding-basic	151.4	153.2	151.5	153.7
Effect of dilutive securities:
Stock options and restricted stock awards and units (in shares)	1.4	1.1	1.5	1.1
Weighted-average number of common shares used in computing diluted net income per common share	152.8	154.3	153	154.8
Net income per common share attributable to Bruker Corporation shareholders:
Basic (in dollars per share)	$ 0.58	$ 0.35	$ 1.33	$ 0.58
Diluted (in dollars per share)	$ 0.57	$ 0.35	$ 1.32	$ 0.57

Earnings Per Share - Anti-dilut

Earnings Per Share - Anti-dilutive Stock Options (Details) - shares shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock options
Anti-dilutive securities
Number of shares excluded from the computation of diluted earnings per share	0	0.3	0	0.1
Unvested restricted stock units
Anti-dilutive securities
Number of shares excluded from the computation of diluted earnings per share	0	0.2	0	0.1

Shareholders' Equity - Share Re

Shareholders' Equity - Share Repurchase and Dividends (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended	9 Months Ended
	May 31, 2021	Sep. 30, 2021	Sep. 30, 2021	May 31, 2019
Shareholders' Equity
Number of shares purchased for issuance under share-based payment arrangement.		0
May 2019 Repurchase Program
Shareholders' Equity
Amount approved for repurchase of common stock				$ 300
Common stock repurchased during the period (in shares)			555,602
Aggregate cost of common stock repurchased during the period			$ 34.5
May 2021 Repurchase Program
Shareholders' Equity
Amount approved for repurchase of common stock	$ 500
Common stock repurchased during the period (in shares)			530,703
Aggregate cost of common stock repurchased during the period			$ 36.6
Remaining authorization amount for repurchase of common stock		$ 463.4	$ 463.4
Stock repurchase program,Purchase of common stock from time to time, period	2 years

Shareholders' Equity - Comprehe

Shareholders' Equity - Comprehensive Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Summary of comprehensive income (loss)
Consolidated net income	$ 88.1	$ 55.3	$ 204.6	$ 90.1
Foreign currency translation adjustments	(26.6)	38.9	(80.2)	42.8
Derivatives designated as hedging instruments, net of tax	10.5	(30.3)	59.3	(37.7)
Pension liability adjustments, net of tax	1.1	0.1	4.4	14.9
Net comprehensive income	73.1	64	188.1	110.1
Less: Comprehensive income attributable to noncontrolling interests	0.7	1.4	0.9	1.5
Less: Comprehensive loss attributable to redeemable noncontrolling interest				(0.5)
Comprehensive income attributable to Bruker Corporation	$ 72.4	$ 62.6	$ 187.2	$ 109.1

Shareholders' Equity - Accumula

Shareholders' Equity - Accumulated Other Comprehensive Income (Details) $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	$ 974.3
Balance at end of period	1,089.6
Foreign Currency Translation
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	140.9
Other comprehensive (loss) income before reclassifications, net of tax	(78.1)
Net current period other comprehensive (loss) income	(78.1)
Balance at end of period	62.8
Derivatives Designated as Hedging Instruments
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	(91.5)
Other comprehensive (loss) income before reclassifications, net of tax	59.3
Net current period other comprehensive (loss) income	59.3
Balance at end of period	(32.2)
Pension Liability Adjustment
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	(45.7)
Other comprehensive (loss) income before reclassifications, net of tax	2.2
Realized loss on amounts reclassified from other comprehensive income, net of tax	2.2
Net current period other comprehensive (loss) income	4.4
Balance at end of period	(41.3)
Accumulated Other Comprehensive Income (Loss)
Summary of the components of accumulated other comprehensive income, net of tax
Balance at beginning of period	3.7
Other comprehensive (loss) income before reclassifications, net of tax	(16.6)
Realized loss on amounts reclassified from other comprehensive income, net of tax	2.2
Net current period other comprehensive (loss) income	(14.4)
Balance at end of period	$ (10.7)

Shareholders' Equity - Expense

Shareholders' Equity - Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 3.8	$ 4.1	$ 10.8	$ 9.9
Cost of revenues
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	0.6	0.6	1.6	1.5
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	2.6	2.9	7.6	6.9
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	0.6	0.6	1.6	1.5
Mestrelab
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	0.3	$ 0.3	$ 1.1	$ 1
Stock options
Additional information
Weighted average remaining service period			2 years 8 months 12 days
Pre-tax stock-based compensation expense Stock options	3.3		$ 3.3
Restricted stock units
Additional information
Weighted average remaining service period			2 years 7 months 6 days
Pre-tax stock-based compensation expense restricted stock units	$ 30.5		$ 30.5

Shareholders' Equity - Share-ba

Shareholders' Equity - Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions (Details)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rates (as a percent)	0.62%	0.23%
Expected life	4 years 5 months 4 days	5 years 1 month 20 days
Volatility (as a percent)	34.00%	34.00%
Expected dividend yield	0.20%	0.37%

Shareholders' Equity - RSU Acti

Shareholders' Equity - RSU Activity (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Restricted stock units
Additional share-based compensation disclosures
Total fair value of shares vested	$ 26.6	$ 12.8
Unvested restricted stock units
Restricted stock, Shares Subject to Restriction
Outstanding at the beginning of the period (in shares)	805,052
Granted (in shares)	216,692
Vested (in shares)	(329,840)
Forfeited (in shares)	(19,043)
Outstanding at the end of the period (in shares)	672,861
Restricted stock, Weighted Average Grant Date Fair Value
Outstanding at the beginning of the period (in dollars per share)	$ 39.63
Granted (in dollars per share)	78.01
Vested (in dollars per share)	37.07
Forfeited (in dollars per share)	43.52
Outstanding at the end of the period (in dollars per share)	$ 53.14

Shareholders' Equity - Stock Op

Shareholders' Equity - Stock Option Activity (Details) $ / shares in Units, $ in Millions	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)
Stock options, Shares Subject to Options
Outstanding at the beginning of the period (in shares) | shares		1,856,176
Granted (in shares) | shares		79,632
Exercised (in shares) | shares		(515,692)
Outstanding at the end of the period (in shares) | shares	1,420,116	1,420,116
Exercisable at the end of the period (in shares) | shares	1,158,452	1,158,452
Exercisable and expected to vest at the end of the period (in shares) | shares	1,384,099	1,384,099
Stock options, Weighted Average Option Price
Outstanding at the beginning of the period (in dollars per share) | $ / shares		$ 25.32
Granted (in dollars per share) | $ / shares		85.10
Exercised (in dollars per share) | $ / shares		20.40
Outstanding at the end of the period (in dollars per share) | $ / shares	$ 30.45	30.45
Exercisable at the end of the period (in dollars per share) | $ / shares	24.66	24.66
Exercisable and expected to vest at the end of the period (in dollars per share) | $ / shares	$ 29.68	$ 29.68
Stock options, additional information
Weighted Average Remaining Contractual Term, Outstanding		4 months 9 days
Weighted Average Remaining Contractual Term, Exercisable	3 months 24 days
Weighted Average Remaining Contractual Term, Exercisable and expected to vest	4 months 6 days
Aggregate Intrinsic Value, Outstanding | $	$ 68.2	$ 68.2
Aggregate Intrinsic Value, Exercisable | $	61.9	61.9
Aggregate Intrinsic Value, Exercisable and expected to vest | $	$ 67.5	67.5
Intrinsic value of options exercised | $		$ 31.8	$ 2.2

Other Charges, Net - Components

Other Charges, Net - Components of other charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Other Charges (Gain), Net
Information technology transformation costs	$ 1.1	$ 0.5	$ 2.6	$ 1.8
Professional fees incurred in connection with investigation matters	0.1	0.3	0.1	4.8
Restructuring charges	0.9	1.7	3.6	4.4
Acquisition-related charges	0.6	0.9	3.8	(1)
Long-lived asset impairments	(0.6)	0.7	(0.6)	1.9
Other		0.1		0.3
Other charges, net	$ 2.1	$ 4.2	$ 9.5	$ 12.2

Other Charges, Net - Restructur

Other Charges, Net - Restructuring Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Restructuring charges
Restructuring expenses	$ 1.6	$ 1.9	$ 5.1	$ 5.7
Cost of revenues
Restructuring charges
Restructuring expenses	0.2	0.2	1.5	1.3
Other charges, net
Restructuring charges
Restructuring expenses	$ 0.9	$ 1.7	$ 3.6	$ 4.4

Other Charges, Net - Restruct_2

Other Charges, Net - Restructuring Reserves (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Changes in the restructuring reserves
Balance at the beginning of the period			$ 9.8
Restructuring charges	$ 1.6	$ 1.9	5.1	$ 5.7
Cash payments			(9.7)
Other, non-cash adjustments and foreign currency effect			(0.8)
Balance at the end of the period	4.4		4.4
Severance
Changes in the restructuring reserves
Balance at the beginning of the period			7.6
Restructuring charges			4.1
Cash payments			(9)
Balance at the end of the period	2.7		2.7
Exit Costs
Changes in the restructuring reserves
Balance at the beginning of the period			0.8
Restructuring charges			1
Cash payments			(0.7)
Other, non-cash adjustments and foreign currency effect			(0.7)
Balance at the end of the period	0.4		0.4
Provisions for Excess Inventory
Changes in the restructuring reserves
Balance at the beginning of the period			1.4
Other, non-cash adjustments and foreign currency effect			(0.1)
Balance at the end of the period	$ 1.3		$ 1.3

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Letters of Credit and Guarantees
Material Accruals For Potential Contingencies	$ 0	$ 0

Business Segment Information (D

Business Segment Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)segment	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Business segment information
Number of reportable segments | segment			3
Total revenue	$ 608.9	$ 511.4	$ 1,734.4	$ 1,360
Operating Income (loss)	113.2	81.2	287.9	135.5
Assets	3,127.7		3,127.7		$ 3,049
Eliminations
Business segment information
Total revenue	(3.7)	(2.9)	(10.5)	(10.1)
Corporate, eliminations and other
Business segment information
Operating Income (loss)	(16.9)	(12.8)	(48.9)	(37.6)
Assets	(6.2)		(6.2)		(4.2)
BSI Life Science | Operating segments
Business segment information
Total revenue	380.7	323.4	1,074.3	842.6
Operating Income (loss)	100.9	80.6	263.4	158.7
Assets	3,038.8		3,038.8		2,964.5
BSI NANO | Operating segments
Business segment information
Total revenue	174.9	147.1	504.6	392.7
Operating Income (loss)	21.8	12.2	55.1	9.3
BEST
Business segment information
Total revenue	57	43.8	166	134.8
BEST | Operating segments
Business segment information
Total revenue	57	43.8	166	134.8
Operating Income (loss)	7.4	$ 1.2	18.3	$ 5.1
Assets	$ 95.1		$ 95.1		$ 88.7